22/23 February 2024
Munich, Germany
On 15 February, the EU Parliament accepted with a large majority the amendmends to the EU directive 2001/83/EC regarding the prevention of the entry of counterfeit medicines into the legal supply chain of medicinal products. The revisions to the directive concern different fields of drug manufacture; especially the securing of quality of pharmaceutical APIs and excipients are concerned.
The new guidance for APIs includes the following:
Considering pharmaceutical APIs, the following new provisions are applicable:
The amended directive will come into force on the 20iest day after the publication in the Official Journal of the European Union. Further changes or a withdrawal of the tightened regulations won't be expectable any longer after the EU Parliament has adopted the revision. After the directive has become operative, the EU Member States will have a 18 month time period to implement the new regulations into their national laws.
Here you can find the currently applicable directive 2001/83/EC and here the final draft to the directive, which won't differ so much from the definitive document.
Author
Dr Gerhard Becker
CONCEPT HEIDELBERG (a service provider entrusted by the ECA Foundation)